Is HURN a Buy or a Sell? The Bull and Bear Case (2026)

Last updated July 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Huron Consulting Group Inc. (HURN) rests on Healthcare demand and the shift toward managed services: Healthcare is the largest segment, at ~$232.3M of RBR in Q2 2026, up ~17% year over year, on segment operating income of ~$69.9M. The bear case rests on the central risk is the one the market has already repriced twice this year: if generative AI compresses the hours clients will pay for, a business built on utilization and staffing leverage degrades fast, and Huron's consulting utilization near ~81% sits closer to the top of its historical range than the bottom. Analysts covering it publish targets from $160.00 to $215.00 against a $151.87 price, so even the professionals disagree by 29% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

Huron Consulting Group was formed in 2002 by former Arthur Andersen partners and has built itself into a global professional services firm organized around three industry segments. Healthcare produced ~50% of revenues before reimbursable expenses in the first half of 2026, Education ~29%, and Commercial ~21%. The work runs through two capabilities: consulting and managed services covers performance improvement, cost reduction, clinical operations, revenue cycle and research administration, while the digital practice implements and then operates enterprise platforms from Workday, Oracle and Salesforce for the same client base. As of June 30, 2026 Huron employed ~5,335 revenue-generating professionals outside managed services, plus ~3,913 managed services staff, a headcount that more than doubled year over year after the RelateCare acquisition added roughly ~1,100 people in patient access. Buying capability is a standing part of the model, with Eclipse Insights, Treliant and WP&C folded in during 2025. The June 2026 quarter was a record on the company's own numbers: revenues before reimbursable expenses of ~$465.6M, up ~15.7% year over year and ~10.8% excluding acquisitions, adjusted EBITDA of ~$72.6M, and management raising full-year RBR guidance to a range of ~$1.85B to ~$1.89B. The share price has told a different story. Shares reached ~$187 at the 52-week high and ~$85 at the low, and the company itself repurchased stock at an average of ~$97 during June, before the late-July report pushed the price back toward ~$152. What moved was the multiple rather than the results, as investors argued over whether generative AI compresses the billable hours consultancies sell. Leverage moved too. Net debt stood at ~$833M and the consolidated leverage ratio at ~2.8x on June 30, against ~1.9x at the end of 2025, the product of ~$208.6M of buybacks in six months alongside deal spending.

The bull case: what would have to be true for $215.00

The most optimistic published target on HURN is $215.00, +41.6% from the $151.87 price as of August 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Healthcare demand and the shift toward managed services

Healthcare is the largest segment, at ~$232.3M of RBR in Q2 2026, up ~17% year over year, on segment operating income of ~$69.9M. Hospital systems under sustained margin pressure keep buying cost, clinical operations and revenue cycle work, which is the least discretionary part of Huron's portfolio. The RelateCare deal added roughly ~1,100 patient access staff and pushes a larger share of segment revenue into recurring managed services contracts rather than project engagements.

2. Education, where budget stress is itself the demand driver

Education RBR was ~$139.4M in Q2 2026, up ~7.8%, with segment operating income of ~$37.4M. Universities facing enrollment softness and unsettled federal research funding tend to buy administrative restructuring and ERP modernization, so pressure on the client is what creates the engagement. Growth here is slower than in the other two segments, but Huron is among the largest Workday and Oracle implementers in higher education, and those relationships are difficult for a rival to dislodge mid-program.

3. Digital, and an AI argument that cuts both ways

Digital capability utilization rose to ~81.8% in Q2 2026 from ~77.8% a year earlier, near the upper end of what a staffing-leverage model can sustain. Management describes proprietary industry data combined with AI tooling as a source of differentiation and pricing power. The opposing case is that AI erodes the pyramid of billable junior hours that funds firms like this one. Reported results so far are consistent with either reading, which is precisely why the multiple has been unstable.

4. A share count that keeps shrinking

Huron repurchased ~1.55M shares for ~$208.6M in the first half of 2026, roughly ~9% of the shares outstanding at the end of 2025, leaving ~$92.0M available under the ~$900M authorization at June 30. Diluted shares used in EPS fell to ~16.4M in Q2 2026 from ~17.8M a year earlier, which is a meaningful part of reported per-share growth. The repurchases were funded in part with revolver borrowings, so the EPS arithmetic carries a balance sheet cost.

The bear case: what would have to be true for $160.00

The most pessimistic published target is $160.00, +5.4% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Huron Consulting Group Inc. is worth if the risks below bite instead of the drivers above.

The central risk is the one the market has already repriced twice this year: if generative AI compresses the hours clients will pay for, a business built on utilization and staffing leverage degrades fast, and Huron's consulting utilization near ~81% sits closer to the top of its historical range than the bottom. Leverage has climbed sharply in six months, to a consolidated leverage ratio of ~2.8x against a ~3.75x covenant limit, which narrows the room for both further buybacks and further acquisitions. The balance sheet carries ~$805M of net goodwill after ~$456M of accumulated impairments from earlier deals, so this is a company that has written down acquisitions before. Education revenue is exposed to university budgets and federal research funding, neither of which is settled. In the Form 10-Q for the quarter ended June 30, 2026, Huron stated it is not party to any litigation management expects to have a material adverse effect, and no securities class action is disclosed.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding HURN already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on HURN

4 analysts cover HURN, with an average target of $190.75 (+25.6% against $151.87) and a split of 5 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the HURN forecast and price target page.

How is HURN valued? (as of August 2026)

Price

$151.87

Market cap

$2.42B

P/E (TTM)

22.84

Forward P/E

14.34

Price / book

5.90

Beta

0.07

52-week range

$84.88 to $186.78

Snapshot for HURN as of August 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM, before reimbursable expenses): ~$1.77B
2026 RBR guidance: ~$1.85B to ~$1.89B
Adjusted diluted EPS guidance (2026): ~$9.00 to ~$9.40
Market cap: ~$2.4B
Forward P/E on 2026 adjusted EPS: ~16x
Net debt: ~$833M (~2.8x leverage)

At roughly ~$152 a share against ~15.9M shares outstanding, Huron carries a market capitalization near ~$2.4B and an enterprise value around ~$3.2B once net debt is counted. That works out to about ~16x the midpoint of management's 2026 adjusted EPS guidance and roughly ~12x guided adjusted EBITDA, below where the larger listed consultancies have typically traded. Trailing GAAP earnings look considerably weaker than the adjusted figures because of intangible amortization, transaction costs and investment write-downs, and the gap between the two is wide enough to be worth re-checking each quarter.

How do you decide if HURN is a buy?

Rather than asking whether HURN is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold HURN indirectly through an index or sector ETF before adding more.

What would change your mind on HURN

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: Healthcare demand and the shift toward managed services stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: the central risk is the one the market has already repriced twice this year: if generative AI compresses the hours clients will pay for, a business built on utilization and staffing leverage degrades fast, and Huron's consulting utilization near ~81% sits closer to the top of its historical range than the bottom fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the HURN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about HURN against your real portfolio and see your actual exposure before deciding.

Investing in Huron Consulting Group Inc. with AI

Connect the broker you already use and ask Walnut's AI how HURN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

See how it fits your portfolio

FAQ

Is HURN a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on Healthcare demand and the shift toward managed services, with revenue (ttm, before reimbursable expenses) at ~$1.77B. The bear case rests on the central risk is the one the market has already repriced twice this year: if generative AI compresses the hours clients will pay for, a business built on utilization and staffing leverage degrades fast, and Huron's consulting utilization near ~81% sits closer to the top of its historical range than the bottom. Analysts covering it are spread from $160.00 to $215.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell HURN?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The central risk is the one the market has already repriced twice this year: if generative AI compresses the hours clients will pay for, a business built on utilization and staffing leverage degrades fast, and Huron's consulting utilization near ~81% sits closer to the top of its historical range than the bottom. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $160.00, +5.4% from the $151.87 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for HURN?

Healthcare demand and the shift toward managed services. Healthcare is the largest segment, at ~$232.3M of RBR in Q2 2026, up ~17% year over year, on segment operating income of ~$69.9M. The most optimistic analyst target on HURN is $215.00, +41.6% from the $151.87 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for HURN?

What does Huron Consulting Group Inc. do?

Global professional services firm providing consulting, digital and managed services to healthcare systems, universities and commercial clients.

What would have to change for HURN to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Healthcare demand and the shift toward managed services) stalling in the reported numbers rather than in the narrative, the risk above (the central risk is the one the market has already repriced twice this year: if generative AI compresses the hours clients will pay for, a business built on utilization and staffing leverage degrades fast, and Huron's consulting utilization near ~81% sits closer to the top of its historical range than the bottom) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Huron Consulting Group do?

Huron is a professional services firm that advises and operates for clients in three industries: healthcare, education and commercial. Services span cost and performance improvement, clinical and revenue cycle operations, research administration, regulatory and financial services consulting, and the implementation and ongoing operation of enterprise software from Workday, Oracle and Salesforce.

How big is each Huron segment?

For the first half of 2026, Healthcare was ~50% of revenues before reimbursable expenses, Education ~29% and Commercial ~21%. In the June 2026 quarter, Healthcare RBR was ~$232.3M, Education ~$139.4M and Commercial ~$94.0M, with segment operating income of ~$69.9M, ~$37.4M and ~$19.8M respectively.

Why did HURN stock fall so far in 2026?

The decline tracked sentiment on AI rather than reported results. Shares dropped sharply after the May 2026 first quarter report despite record revenue and reaffirmed guidance, as investors questioned whether generative AI erodes the billable-hours model across consulting. The stock traded as low as ~$85 before the July 2026 second quarter beat and guidance raise recovered it toward ~$152.

Walnut is informational, not investment advice, and gives no verdict on HURN. Analyst targets referenced here come from a August 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.